Vancouver-based Aspect Biosystems has raised an impressive USD $115 million in Series B funding, signaling a major step forward in the development of bioprinted tissue therapeutics. The financing round was led by Dimension, a life sciences and technology-focused investment firm, with participation from new and returning investors including Novo Nordisk, Radical Ventures, InBC, and others. […]
Aspect Biosystems
Aspect Biosystems Secures $72.75M for Bioprinted Tissue Therapeutics
Vancouver biotech Aspect Biosystems today announced that it has received a $72.75 million investment from the Governments of Canada and British Columbia. The UBC Spinout is pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases and was named to Fast Company’s annual Next Big Things in Tech list last year. […]
Aspect Biosystems Named to Fast Company’s 2023 List of the Next Big Things in Tech
UBC spinout Aspect Biosystems has been named to Fast Company’s third annual Next Big Things in Tech list, honoring technological breakthroughs that promise to shape the future of industries — from healthcare and security to artificial intelligence and data. Aspect Biosystems is applying its full-stack tissue therapeutic platform to develop a novel class of cell-based tissue […]
BC Tech Crowns Winners of 2023 Technology Impact Awards
Tonight the Technology Impact Awards (TIAs) marked their 30th Anniversary announcing 9 companies as award winners and inducting 8 leaders to the Innovators Hall of Fame at the annual awards show. “BC Tech is proud to have played a part in the journey of so many BC tech icons and success stories across our 30-year […]
BC Tech Unveils Finalists For 2023 Technology Impact Awards
The BC Tech Association has announced the finalists for the 2023 Technology Impact Awards, the 30th anniversary of the TIAs. The announcement was hosted in downtown Vancouver at The Den at Bentall Centre with a live online audience. “This year marks a big milestone for BC Tech, as we celebrate our 30th Anniversary alongside the companies […]
Aspect Biosystems Inks $75 Million Deal with Novo Nordisk to Develop Bioprinted Tissue Therapeutics for Diabetes and Obesity
UBC spinout Aspect Biosystems is collaborating with Novo Nordisk to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology […]
Aspect Biosystems Aims to Pioneer Regenerative Medicine with 3D Tech
A recent investment from the Pacific Economic Development Agency of Canada will help broaden the application of Aspect Biosystems’ 3D bioprinting technology for therapeutic development, expand its global network of partners, and scale-up its manufacturing systems, according to a statement issued by the Vancouver firm. Aspect, among other Vancouver tech companies receiving funding from PacifiCan’s […]
Government of Canada Invests $16 Million In 8 Vancouver Tech Companies
The Honourable Harjit S. Sajjan, Minister of International Development and Minister responsible for the Pacific Economic Development Agency of Canada (PacifiCan), has announced an investment of over $25.7 million to help 10 Vancouver-based organizations fuel the B.C. economy. The investment includes over $16 million for eight companies through the Business Scale-Up and Productivity program and over $9 million for […]
Canada Highlights Support For Innovation In British Columbia
As Canadians begin to look toward economic recovery, Canada’s small and medium-sized enterprises (SME) will be the backbone of economic growth in communities across the country. These firms are already supporting more than 10 million jobs for Canadian workers, and many of them are making groundbreaking discoveries to improve Canadians’ lives and drive innovation and technology. To […]
Aspect Biosystems Offers Novel Solution For Treating Type 1 Diabetes
Vancouver’s Aspect Biosystems is working on a novel technological and genomics-based approach to Type 1 Diabetes that promises to circumvent the shortcomings of current treatments. Aspect is producing a bioprinted therapeutic of pancreatic cells surrounded by a protective layer that can be implanted in Type 1 Diabetes patients. Type 1 Diabetes (T1D), once known as […]